Skip to main content

Table 1 Clinicopathologic characteristics of participants

From: Biomechanical parameters quantified by MR elastography for predicting response to neoadjuvant chemotherapy and disease-free survival in breast cancer: a prospective longitudinal study

Characteristics

pCR status

Recurrence status

pCR

Non-pCR

P value

Recurrence

No recurrence

P value

No. of Patients

62 (26)

173 (74)

 

23 (10)

212 (90)

 

Age, mean ± SD, years (range)

50.85 ± 6.80 years

(range, 32 ~ 63 years)

50.40 ± 8.57 years

(range, 22 ~ 70 years)

0.71§

50.46 ± 8.21 years

(range, 39 ~ 68 years)

51.09 ± 7.45 years

(range, 22 ~ 70 years)

0.73§

Menstruation status

      

 Premenopausal

23 (37)

75 (43)

0.86

6 (23)

92 (43)

0.11

 Postmenopausal

39 (63)

98 (57)

17 (73)

120 (57)

Position

      

 Right

32 (52)

86 (49)

0.80

13 (56)

105 (49)

0.52

 Left

30 (48)

87 (51)

10 (44)

107 (51)

Location

      

 Upper outer quadrant

35 (56)

110 (64)

0.69*

16 (68)

129 (61)

0.29*

 Upper inner quadrant

10 (16)

23 (13)

4 (17)

29 (14)

 Lower outer quadrant

13 (21)

27 (16)

1 (5)

39 (18)

 Lower inner quadrant

4 (7)

13 (7)

2 (10)

15 (7)

ER

      

 positive

22 (35)

119 (69)

< 0.001

9 (39)

132 (62)

0.03

 negative

40 (65)

54 (31)

14 (61)

80 (38)

PR

      

 positive

4 (6)

83 (48)

< 0.001*

3 (13)

84 (40)

0.012*

 negative

58 (94)

90 (52)

20 (87)

128 (60)

HER-2

      

 positive

42 (68)

52 (30)

< 0.001

3 (13)

91 (43)

0.006*

 negative

20 (32)

121 (70)

20 (87)

121 (57)

Ki67

      

 positive

54 (87)

137 (79)

0.17

22 (96)

169 (80)

0.09*

 negative

8 (13)

36 (21)

1 (4)

43 (20)

Molecular subtype

      

 Luminal A

0 (0)

26 (15)

< 0.001*

1 (4)

25 (12)

0.022*

 Luminal B

22 (35)

92 (53)

7 (30)

107 (50)

 HER2-enriched

28 (45)

23 (13)

11 (48)

40 (19)

 TNBC

12 (20)

32 (19)

4 (18)

40 (19)

cT stage

      

 1

3 (5)

9 (5)

0.053*

0 (0)

12 (5)

0.11*

 2

34 (55)

88 (51)

8 (35)

114 (54)

 3

15 (24)

23 (13)

7 (30)

31 (15)

 4

10 (16)

54 (31)

8 (35)

56 (26)

 cN stage

      

 0

7 (11)

20 (12)

0.46

2 (8)

25 (12)

0.005*

 1

23 (37)

52 (30)

1 (4)

74 (35)

 2

20 (32)

75 (43)

14 (62)

81 (38)

 3

12 (20)

26 (15)

6 (26)

32 (15)

Clinical stage

      

 IIA

7 (11)

14 (8)

0.14

1 (4)

20 (9)

0.044*

 IIB

15 (24)

25 (14)

0 (0)

40 (19)

 IIIA

20 (32)

65 (38)

12 (53)

73 (35)

 IIIB

8 (13)

43 (25)

4 (17)

47 (22)

 IIIC

12 (20)

26 (15)

6 (26)

32 (15)

Cycles of NAC

      

 4 cycles

8 (13)

27 (16)

0.02

1 (4)

34 (16)

0.33*

 6 cycles

46 (74)

95 (55)

15 (65)

126 (59)

 8 cycles

8 (13)

51 (29)

7 (31)

52 (25)

NAC response

      

 pCR

   

2 (9)

60 (28)

0.047*

 Non-pCR

   

21 (91)

152 (72)

  1. Note.—Unless otherwise specified, data are numbers of patients, with percentages in parentheses. pCR = pathological complete response, SD = standard deviation, ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal growth factor receptor-2, TNBC = triple negative breast cancer, NAC = neoadjuvant chemotherapy
  2. Unless otherwise noted, P values were obtained using the chi-square test
  3. §Two-tailed Student t test with unequal variance was used
  4. *The Fisher exact test was used for categorical variables
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us